Biotech China 2014

Pharmacology: University of Texas, MD Anderson

Total Score People Score Events Score
28 25 6
Date Event Presentation Speakers
April 6, 2013 AACR Annual Meetings Drug Discovery in Industry, Academia, and Government: What Is the Track Record? Michael A. White
Clinical Trial Design in the Genomic Era Co-Chairpersons: Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX, and George W. Sledge, Jr., Stanford University School of Medicine, Stanford, CA Donald Berry
Rational Combination Therapies in Cancer Chairperson: Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX Gordon Mills
Bridging the Gap Between Clinical Research and Laboratory Investigation: Utilizing Presurgical Clinical Trials to Investigate Anti-CTLA-4 Immunotherapy Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX Padmanee Sharma
Whole Body Metabolism and Cancer Chairperson: Philipp E. Scherer, UT Southwestern Medical Center, Dallas, TX Philipp Scherer
Tumor-Secreted Factors Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY George A. Calin
Identifying Novel Redox Signaling Pathways for Cancer Chemoprevention: From Fly to the Mouse Garth Powis, The University of Texas MD Anderson Cancer Center, Houston, TX Garth Powis
PAK Family of Kinases in Human Cancer: Past, Present, and Future Rakesh Kumar, George Washington University, Washington, DC Rakesh Kumar
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer Session 2 | PI3K Pathway Aberrations in Human Cancer Gordon Mills
mTORC1 regulation by TSC2 Cheryl Lyn Walker
Predictors and pharmacodynamic markers of rapamycin response Funda Meric-Bernstam
Session 4 | Targeting mTOR Funda Meric-Bernstam
Targeting the PI3K/AKT/mTOR pathway in the clinic: Early results from the PREDICT program Razelle Kurzrock
Session 8 | Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials II Funda Meric-Bernstam
Overcoming challenges to targeting the PI3K pathway in cancer Gordon Mills
Molecular marker-based clinical trial designs to target the PI3K pathway Ana Gonzalez-Angulo
Session 7 | Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials I Funda Meric-Bernstam
February 13, 2011 Inositide Signaling in Pharmacology and Disease (X1) PI 3-Kinases (X2) | Workshop 1: Monitoring Phosphoinositide Activation in Signaling and Disease Gordon Mills
PI 3-Kinases (X2) | A Systems Biology Approach to Monitor the PI3K Pathway Gordon Mills
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Crystallographic Studies of CYP46A1 Irina A. Pikuleva
May 30, 2008 ASCO Annual'08 Meeting breast cancer-- Postmenopausal Hormone Therapy: Friend or Foe? (M19) Peter Ravdin
cancer genetics-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun Margaret R. Spitz
cancer prevention/epidemiology-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun Margaret R. Spitz
cancer prevention/epidemiology-- Postmenopausal Hormone Therapy: Friend or Foe? (M19) Peter Ravdin
developmental therapeutics-- c-MET Inhibition for Cancer Treatment Razelle Kurzrock
developmental therapeutics-- Issues in the Modulation of Angiogenesis Pathways (M10) Roy S. Herbst
developmental therapeutics-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials? Chris H. Takimoto
gastrointestinal (colorectal) cancer-- Advances in Anal Cancer Management (M01) Cathy Eng
gastrointestinal (colorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy Cathy Eng
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A) James C. Yao
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B) James C. Yao
gastrointestinal (noncolorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy Cathy Eng
gastrointestinal (noncolorectal) cancer Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials? Chris H. Takimoto
genitourinary cancer-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies CPO20A) Paul Mathew
genitourinary cancer What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B) Paul Mathew
gynecologic cancer-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20) Maurie Markman
lung cancer-- Therapeutic Modalities for “Small” Stage I Lung Cancers Robert Timmerman
lymphoma and plasma cell disorders-- The Role of Maintenance Therapy in Follicular Lymphoma: Pros and Cons Peter McLaughlin
patient and survivor care-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20) Maurie Markman
patient and survivor care-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials? Chris H. Takimoto
sarcoma/bone and soft tissue cancers-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12) Shreyaskumar Patel
tumor biology-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12) Shreyaskumar Patel
meet the professor sessions-- Advances in Anal Cancer Management (M01) Cathy Eng
meet the professor sessions-- Issues in the Modulation of Angiogenesis Pathways (M10) Roy S. Herbst
meet the professor sessions-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20) Maurie Markman
meet the professor sessions-- Postmenopausal Hormone Therapy: Friend or Foe? (M19) Peter Ravdin
meet the professor sessions-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12) Shreyaskumar Patel
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A) James C. Yao
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B) James C. Yao
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20A) Paul Mathew
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B) Paul Mathew
October 16, 2007 Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17) MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT(11:10-16:30) Madeleine Duvic
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Discussion- Are HDAC Inhibitors Proving Their Worth in the Clinic? (14:25-15:25) Madeleine Duvic
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.